Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

$5 to $7 Net Income (Loss) (GAAP) $(15) to $0 Stock Compensation Expense $32 to $35 Net Income (non-GAAP) $17 to $35 * Excludes upfront research and development expenses associated with the Riquent deal ** Represents upfront costs associated with the Riquent deal to be allocated between research and development expense and investment impairment

BioMarin estimates that top line product revenue will grow approximately 20% to 25% in 2010 and approximately 15% to 20% in 2011. These revenue estimates reflect growth from existing commercial products and do not include potential sales from additional new products. BioMarin expects GAAP net income in the range of $35 million to $40 million in 2010 and in the range of $60 million to $65 million in 2011. Excluding stock compensation expense, non-GAAP net income is projected to be in the range of $70 million to $80 million in 2010 and in the range of $95 million to $105 million in 2011. These estimates are based on BioMarin's current business plan and do not include the effect of any significant business development transaction that the company may choose to do in the future.

Non-GAAP Financial Information and Reconciliation

The above results for the fourth quarter and full year of 2007 and 2008 and financial guidance for 2009, 2010 and 2011 include actual and Management's 2009, 2010 and 2011 estimated net income, respectively, determined in accordance with GAAP and non-GAAP net income. As used in this release, non-GAAP income is net income calculated in accordance with GAAP, but excluding non-cash stock compensation expense, a non-GAAP financial measure. Stock compensation expense excluded in the calculation of non-GAAP net income was $7.4 million for the fourth quarter of 2008, $5.5 million for the fourth quarter of 2007
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... and EMERYVILLE, Calif., May 14 Bayer HealthCare Pharmaceuticals, ... ) today announced that more than 65 studies evaluating ... at the 2009 American Society of Clinical Oncology (ASCO) ... cancers - in the treatment of unresectable hepatocellular carcinoma ...
... and Phase 1 safety studies, and plans for Phase ... (BPH) are to be presentedCINCINNATI, May 14 Ausio ... for an aging global population, will lead off the ... 2009 at 9:00 AM in Atlanta, Georgia. Ausio has ...
... Non-Invasive Imaging to Demonstrate Mechanism of Action and Positive ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... 2 clinical trial of its lead drug, VIA-2291 in ...
Cached Biology Technology:Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting 6Ausio Pharmaceuticals to Present at Bio(R) 2009 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:4/23/2014)... 2 million Food Standards Agency (FSA) project to map ... workers. , Norovirus outbreaks can rapidly affect large ... frozen strawberries infected 11,000 people in Germany, but there ... strains cause infection and which foods are the most ... will produce data that will help the FSA to ...
(Date:4/22/2014)... will lead a five-year, $3 million study to determine ... the transport of dissolved organic matter (DOM) through the ... the chemical composition and water quality of the watershed ... National Science Foundation,s MacroSystems Biology program, researchers will collect ... begins in Canada and runs through five U.S. states, ...
(Date:4/22/2014)... Calif. Inspired by the fist-like club of ... University of California, Riverside, in collaboration with University of ... structure for composite materials that is more impact resistant ... "The more we study the club of this tiny ... so many things we use every day," said David ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... the body of pathogens. As important as resisting infection, is ... toxins produced by pathogens or by components of the host ... damage inflicted to different tissues and organs that, if uncontrolled, ... , The in-built capacity that an infected individual has ...
... LANSING, Mich. In the current issue of Science ... virus evolves, which sheds light on how easy it can ... showed for the first time how the virus called "Lambda" ... an innovation that took four mutations to accomplish. This virus ...
... magician employing sleight of hand, the protein mitoNEET -- a ... draws the eye with a flurry of movement in one ... else. Using a combination of laboratory experiments and computer ... San Diego (UCSD) have deciphered part of mitoNEET,s movements to ...
Cached Biology News:European Research Council supports search for regulators of tissue damage 2MSU researchers show how new viruses evolve, and in some cases, become deadly 2Rice, UCSD scientists probe form, function of mysterious protein 2Rice, UCSD scientists probe form, function of mysterious protein 3
... Vybrant Apoptosis Assay Kit #4 ... that occur in the permeability of cell ... both YO-PRO-1 and propidium iodide nucleic acid ... plasma membranes of apoptotic cells and labels ...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
Request Info...
Biology Products: